HIV/AIDS Treatment as Prevention strategy working in B.C. Montaner calls for national implementation
Media Release | November 27, 2012
A new study from the BC Centre for Excellence in HIV/AIDS (BC-CfE) shows highly active antiretroviral therapy (HAART) reduces new HIV diagnoses, deaths and HIV prevalence, suggesting that the made-in-Canada Treatment as Prevention strategy should be implemented across the country.
Media Release | November 20, 2012
HIV-positive individuals who strictly adhere to highly active antiretroviral therapy (HAART) have a significantly lower probability of premature morbidity and mortality as compared to those with suboptimal compliance to HAART, according to a new study from the BC Centre for Excellence in HIV/AIDS (BC-CfE).
Media Release | September 10, 2012
Researchers with the Neglected Global Diseases Initiative (NGDI) at the University of British Columbia have attracted more than $20 million in funding to find ways to eliminate diseases and conditions that kill millions of people in developing countries worldwide.
Media Release | June 5, 2012
A drug delivery system developed through the University of British Columbia’s Neglected Global Diseases Initiative and licensed to iCo Therapeutics Inc. will receive $1.1 million from the National Research Council of Canada (NRC) for clinical development as a treatment for HIV patients.
Media Release | May 15, 2012
Daniel Werb, senior research assistant at the Addiction and Urban Health Research Initiative (UHRI) at the BC Centre for Excellence in HIV/AIDS (BC-CfE), has been awarded the 2012 Pierre Elliott Trudeau Foundation Doctoral Scholarship for his PhD research project investigating initiation and cessation of injection drug use among street youth in Vancouver.
Media Release | October 18, 2011
An independent reviewer has dismissed concerns over a study that shows a 35-per-cent decrease in overdose deaths after the opening of Insite, North America’s only supervised injection facility.